ACL/FOR + Placebo
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedAbout ACL/FOR + Placebo
ACL/FOR + Placebo is a approved stage product being developed by AstraZeneca for COPD. The current trial status is completed. This product is registered under clinical trial identifier NCT02429765. Target conditions include COPD.
What happened to similar drugs?
20 of 20 similar drugs in COPD were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02429765 | Approved | Completed |
Competing Products
20 competing products in COPD